anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain an immunological diagnostic reagent having good storage stability, by compounding calcium bromide in an aqueous dispersion of water- dispersible macromolecular polymer particles having an immunologically active substance immobilized therewith through a covalent bond. CONSTITUTION:The average particle size of a water-dispersible macromolecular polymer particles being a carrier for immobilizing an immunologically active substance is especially pref. 0.1-1mum and the specific gravity thereof is pref. in a range of 0.9-1.5. The polymer particles have a functional group for bonding the immunologically active substance as an essential condition and, as the functional group, a carboxyl group, an amino group, a hydroxyl group or the like are pref. The aqueous dispersion of the water-dispersible macromolecular polymer particles is obtained by the emulsion copolymerization of a vinyl monomer having a carboxyl group such as a monobasic or polybasic acid such as acrylic acid, methacrylic acid, itaconic acid or crotonic acid. Calcium bromide is compounded in the aqueous dispersion as an additive for suppressing non-specific flocculation of particles.
To explore the predictive value of mitral annular plane systolic excursion (MAPSE) derived by cardiac magnetic resonance (CMR) for major adverse cardiovascular events (MACE) in postmyocardial infarction (MI) patients. Patients with MI who underwent 3.0 T CMR (Chinese Clinical Trial Registry, ChiCTR2200055158) were recruited retrospectively. CMR parameters included MAPSE and LVEF. Patients were followed up for MACE for more than 6 months and were separated into a No-MACE group and a MACE group. A total of 165 post-MI patients were included, and 103 patients were finally analyzed (61 patients belonged to the No-MACE group, and 42 patients belonged to the MACE group). The LVEF and MAPSE of the patients belonging to the No-MACE group were considerably higher than those of the patients belonging to the MACE group. Both LVEF and MAPSE were effective indicators of the occurrence of MACE after MI. The risk of MACE decreased as LVEF and MAPSE increased. For the risk prediction of MACE after MI, compared with model I (chi-square value 4.0 vs. 31.4, P < 0.001) and model II (chi-square value 22.7 vs. 31.4, P = 0.003), model III had a significant incremental predictive value. Moreover, the cutoff value of MAPSE was 9.70 mm. CMR-derived MAPSE is an effective predictor of MACE occurrence in patients with MI, and MAPSE provided a significant incremental predictive value. Moreover, MAPSE could complement LVEF for superior risk stratification of MI patients.
Pulmonary hypertension (PH) is a descriptive name for abnormally elevated pressures in the pulmonary vasculature, which seriously affects the quality of life and survival of patients. Currently, no effective drugs treatment was used in patients with pulmonary hypertension due to acute exacerbation of lung disease. Recombinant Human Brain Natriuretic Peptide (rhBNP)was approved in 2001 for use in patients with acute heart failure on the basis of studies showing a reduction in pulmonary-capillary wedge pressure(PCWP) and pulmonary arterial pressure (PAP) and improvement cardiac output (CO) . Thus, the study was designed to administer rhBNP as a continuous infusion for 24 hours on pulmonary hypertension of acute exacerbations of chronic pulmonary disease monitoring by Swan- Ganz catheter. Each patient was studied on two occasions (6 hours apart). One occasion the subject received rhBNP 1.5ug/kg IV bolus followed by an infusion of 0.0075ug/kg/min for 24 hours; other occasion the subject received IV placebo bolus followed by a placebo infusion for 24 hours .these were administered in random order in double blind fashion.
FIELD: organic chemistry, amino acids, pharmacy. SUBSTANCE: invention relates to the composition with antifungal activity containing at least one cyclopentane-beta-amino acid and/or its derivative of the general formula (Ib)   where R 1  and R 2  in common mean residue of the formula =CH 2 ; R 6  and Y mean hydrogen atom and at least one alpha-amino acid and/or its derivative of the formula (Ia)   additionally where R 3  means linear or branched C 1 -C 8 -alkyl; R 4  and R 5  means hydrogen X means hydroxyl and alpha-amino acid and/or its derivative and cyclopentane-beta- amino acid and/or its derivative are taken in the molar ratio from 1: 1 to 1:5. Invention relates to also dipeptide of the general formula (A)   where R 1 -R 6  are given above; X and Y mean a moiety of covalent bond of alpha-amino acid and cyclopentane-beta-amino acid. Invention relates to also a pharmaceutical composition with antifungal activity containing at least one dipeptide of the formula (A) as an active substance taken in effective amount and nontoxic pharmaceutically inert carrier. EFFECT: valuable antifungal properties of composition. 4 cl, 1 tbl, 7 ex
A hair composition comprising (a) a hydroxypropyl guar hydroxypropyltrimonium chloride having an average molecular weight ranging from 2,000,000 to 3,500,000 g/mol; and (b) one or more protein hydrolysates is provided. The hydroxypropyl guar hydroxypropyltrimonium chloride may have a viscosity ranging from 600 to 1200 mPa.s. The protein hydrolysate may be selected from hydrolysates of animals and/or plant proteins. The hydrolysates may be selected from milk protein hydrolysates; keratin hydrolysates; wheat protein hydrolysates; maize protein hydrolysates; rice protein hydrolysates; potato protein hydrolysates; soya protein hydrolysates; almond protein hydrolysates; or algae protein hydrolysates. The protein hydrolysate may comprise or consist of hydrolysed hemp seed extract and hydrolysed rice protein, or it may comprise or consist of hydrolysed keratin. The hair composition may be a hair shampoo. The composition may further comprise 5 to 50 wt% of at least one anionic, nonionic, amphoteric or zwitterionic surfactant. The composition may be a hair conditioner which may comprising 0.1 to 15 wt% of at least one cationic surfactant. A method of repairing split ends comprising applying to the hair the hair composition is provided.
Patient lied prone; the treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers with the instrument at a 45º angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45º angle for an additional 20-second, resulting in a total treatment time of approximately 40 s. This technique was applied 3-5 times per session with 20 s rest between each time. Three times passive stretching of the upper trapezius muscle was also performed for 45 s for each side.
PROBLEM TO BE SOLVED: To obtain a collunarium for rhinitis containing a vasoconstrictor and ketotifen fumarate, useful for eliminating or alleviating various symptoms of rhinitis, especially inflammatory symptoms including tumidity of nasal mucous membrane. SOLUTION: This collunarium contains 0.01-0.75wt.% of vasoconstrictor and 0.005-1wt.% of ketotifen fumarate as active ingredients. The nasal drop contains preferably further at least one kind of compound selected from flunisolide, prednisone, beclometasone dipropionate and fulticasone dipropionate. Naphazoline, tetrahydrozoline, oxymetazoline or salts of those can be exemplified as the vasoconstrictor. A local anesthetic, cholinergic-blocking agent, antiinflammatory enzyme agent, antiphlogistic, bactericide, vitamin, crude drug, etc., are properly blended with the main ingredients and the blend is prepared in a solid atomizing medicine or a liquid atomizing medicine according to the ordinary manner. The collunarium highly effective in eliminating or alleviating symptoms of rhinitis can be obtained by combining the above two active ingredients.
A cannabidiol (CBD) preparation for use in the treatment of seizures associated with bilateral cerebral dysgenesis (brain malformation) is provided. The seizures associated with bilateral cerebral dysgenesis may be tonic, atonic and focal seizures with impairment and spasms. The CBD preparation may comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The CBD preparation may comprise CBD isolated from cannabis plant material or may be synthetic CBD. The CBD preparation may be used in combination with one or more concomitant anti-epileptic drugs (AED). The one or more concomitant AEDs may be selected form the group consisting of lorazepam, brivaracetam, vigabatrin, zonisamide and clobazam. The dose of CBD may be between 5 mg/kg/day to 50 mg/kg/day. A clinical trial is disclosed wherein a patient diagnosed with bilateral cerebral dysgenesis had a decrease in the amount of tonic, atonic, focal seizures with impairment and spasms after dosing with the CBD preparation and concomitant AEDs.
Currently, various antimitotic inhibitors applied in tumor therapy. However, these inhibitors exhibit targeted toxicity to some extent. As a motor protein, kinesin family member 18A (KIF18A) is crucial to spindle formation and is associated with tumors exhibiting ploidy-specific characteristics such as chromosomal aneuploidy, whole-genome doubling (WGD), and chromosomal instability (CIN). Differing from traditional antimitotic targets, KIF18A exhibits tumor-specific selectivity. The functional loss or attenuation of KIF18A results in vulnerability of tumor cells with ploidy-specific characteristics, with lesser effects on diploid cells. Research on inhibitors targeting KIF18A with ploidy-specific lethality holds significant importance. This review provides a brief overview of the regulatory mechanisms of the ploidy-specific lethality target KIF18A and the research advancements in its inhibitors, aiming to facilitate the development of KIF18A inhibitors.
Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
BACKGROUND: Delirium is a common and reversible neurobehavioral condition with significant morbidity and mortality ramifications for older patients. Consequentially, clear guidelines exist pertaining to its swift identification and management. However, studies suggest that adherence to these guidelines are poor. This audit aimed to evaluate compliance to the National Institute for Health and Care Excellence's (NICE) delirium guidelines in an Acute Senior Health Unit (ASHU) and to present a single centre experience of a low-cost ward-based intervention for improving delirium guideline adherence.
METHODS: A retrospective observational audit was conducted on patients admitted to ASHU between 01/07/2023 and 30/07/2023. Data on delirium assessments, diagnoses and causes of delirium were obtained through retrospective database searches. Posters and education based multidisciplinary team (MDT) interventions were designed and initiated following grounded thematic literature analysis and ward discussion. A methodically equivalent audit was then conducted between 01/09/2023 and 30/09/23. Data was anonymised and blinded and analysis was performed on SPSS V12.0.
RESULTS: A total of 128 patients were included in the study. Initial audit revealed suboptimal compliance with NICE recommendations. Chi-square test of independence found that patients were statistically more likely to receive a full delirium assessment (1.9% vs. 56.6%, p = 0.001) and formal diagnosis (5.8% vs. 27.6%, p = 0.002) after the ward-based intervention.
CONCLUSION: This study provides limited evidence in favour of low-cost MDT based interventions for improving adherence to NICE delirium guidelines and provides a 5-step framework for future studies. This study also explores the potential patient implications of these interventions. A repeat audit should be conducted to ensure lasting and sustainable change is achieved.
TRIAL REGISTRATION/CLINICAL TRIAL NUMBER: AUDI003614.
PURPOSE: Lymph node status is a determinant of survival in patients with early-stage cervical cancer. However, the relationship between obesity and lymph node status remains unclear. Therefore, this systematic review aims to evaluate the correlation between body mass index (BMI) and lymph node metastasis in cervical cancer.
METHODS: Cohort studies through six databases were reviewed until December 2021. Odds ratios (ORs) for lymphatic metastasis were estimated using random-effects models and network meta-analysis. BMI groups for lymph node metastasis were ranked. Heterogeneities were assessed using I2. Subgroup analyses were performed to determine possible sources of heterogeneity.
RESULTS: No significant difference was found between obese (BMI ≥ 25) and non-obese patients (BMI < 25) (OR = 1.01; 95% CI 0.69-1.47; P = 0.97). In subgroup analyses, obesity was associated with higher risk among the Americans and advanced-stage patients. The grouping analysis based on BMI and the rankogram values revealed that the '35 ≤ BMI' group had the highest risk of lymph node metastasis.
CONCLUSION: Although there were no significant differences in lymph node metastasis between obese and non-obese cervical cancer patients in overall analysis, patients with BMI ≥ 35 were at significantly higher risk of lymph node metastasis.
OncoSweep Cancer Spotlight and Spectrum Product Lines are qualitative in vitro diagnostic devices testing plasma specimens for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA analysis, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR) and next-generation sequencing (NGS). This is a two-arm, open-label, non-randomized controlled pilot study intends to screen adults 18 years or older, who are treatment-naïve for cancers and have pulmonary nodules or mass detected by low-dose computerized tomography (LDCT) or standard computerized tomography (CT) scans. OncoSweep Lung Spotlight will be utilized with venous blood samples collected in the healthcare facility where the study is being conducted. The X-ray, LDCT/ standard CT scan, blood laboratory test data, or biopsy results will be collected from the control group, and the blood sample will be analyzed by OncoSweep Lung Spotlight. Results generated from both groups will be evaluated against each other. The result of OncoSweep Lung Spotlight provides additional evidence to support or assist medical diagnoses when used in combination with LDCT/ standard CT scan data.
<P>PROBLEM TO BE SOLVED: To provide a new component which has a skin-lightening action of a microorganism origin.  <P>SOLUTION: The skin-lightening composition includes a fermentation product by Monascus pilousus. The fermentation product is preferably a fermentation product of fermenting a soybean by the Monascus pilousus. The skin-lightening composition further preferably includes an ethanol extract of the fermentation product by the Monascus pilousus as an active ingredient. The present invention also relates to a skin-lightening cosmetic and a skin-lightening foodstuff including the skin-lightening composition.  <P>COPYRIGHT: (C)2010,JPO&INPIT
A hair roots coloring kit includes a plurality of kit components carried in a drawstring bag for mixing and applying standard hair coloring materials to the uncolored outgrown roots of a user's hair. One or more measuring devices such as a measuring cup, a syringe, or an eyedropper are used for measuring the hair coloring materials to produce a matching color to previously colored hair shafts of the hair. A reusable mixing bowl or a plurality of disposable mixing bowls hold the measured hair coloring materials. A reusable stirring stick or a plurality of disposable stirring sticks are provided for mixing together the measured hair coloring materials in the mixing bowl. An applicator brush is used for applying the mixed matching color of hair coloring composition to the uncolored hair roots. A pair of protective gloves are provided to protect the user's hands during application of the hair coloring composition to the hair roots. A cleaning brush is used to aid in cleaning the kit components following use.
The total duration of all techniques applied is 30 minutes. The techniques used in the extremities were applied to both extremities.
BACKGROUND AND OBJECTIVE: Among many treatment approaches for chronic low back pain (CLBP), self-management techniques are becoming increasingly important. The aim of this paper was to (a) provide an overview of existing digital self-help interventions for CLBP and (b) examine the effect of these interventions in reducing pain intensity, pain catastrophizing and pain disability.
DATABASES AND DATA TREATMENT: Following the PRISMA guideline, a systematic literature search was conducted in the MEDLINE, EMBASE, PsychInfo, CINAHL and Cochrane databases. We included randomized controlled trials from the last 10 years that examined the impact of digital self-management interventions on at least one of the three outcomes in adult patients with CLBP (duration ≥3 months). The meta-analysis was based on random-effects models. Standardized tools were used to assess the risk of bias (RoB) for each study and the quality of evidence for each outcome.
RESULTS: We included 12 studies (n = 1545). A small but robust and statistically significant pooled effect was found on pain intensity (g = 0.24; 95% CI [0.09, 0.40], k = 12) and pain disability (g = 0.43; 95% CI [0.27, 0.59], k = 11). The effect on pain catastrophizing was not significant (g = 0.38; 95% CI [-0.31, 1.06], k = 4). The overall effect size including all three outcomes was g = 0.33 (95% CI [0.21, 0.44], k = 27). The RoB of the included studies was mixed. The quality of evidence was moderate or high.
CONCLUSION: In summary, we were able to substantiate recent evidence that digital self-management interventions are effective in the treatment of CLBP. Given the heterogeneity of interventions, further research should aim to investigate which patients benefit most from which approach.
SIGNIFICANCE: This meta-analysis examines the effect of digital self-management techniques in patients with CLBP. The results add to the evidence that digital interventions can help patients reduce their pain intensity and disability. A minority of studies point towards the possibility that digital interventions can reduce pain catastrophizing. Future research should further explore which patients benefit most from these kinds of interventions.
Background: Acute myocardial infarction (AMI) is a critical cardiovascular disease with high morbidity and mortality. Identifying practical parameters for predicting long-term mortality is crucial in this patient group. The percentage of mean arterial pressure (%MAP) is a useful parameter used to assess peripheral artery disease. It can be easily calculated from ankle pulse volume recording. Previous studies have shown that %MAP is a useful predictor of all-cause mortality in specific populations, but its relationship with mortality in AMI patients is unclear. Methods: In this observational cohort study, 191 AMI patients were enrolled between November 2003 and September 2004. Ankle-brachial index (ABI) and %MAP were measured using an ABI-form device. All-cause and cardiovascular mortality data were collected from a national registry until December 2018. Cox proportional hazards model and Kaplan-Meier survival plot were used to analyze the association between %MAP and long-term mortality in AMI patients. Results: The median follow-up to mortality was 65 months. There were 130 overall and 36 cardiovascular deaths. High %MAP was associated with increased overall mortality after multivariable analysis (HR = 1.062; 95% CI: 1.017-1.109; p =0.006). However, high % MAP was only associated with cardiovascular mortality in the univariable analysis but became insignificant after the multivariable analysis. Conclusions: In conclusion, this study is the first to evaluate the usefulness of %MAP in predicting long-term mortality in AMI patients. Our study shows that %MAP might be an independent predictor of long-term overall mortality in AMI patients and has better predictive power than ABI.
The effectiveness of LOKELMA in lowering serum potassium was demonstrated in a two-part, double-blind, randomized, placebo-controlled clinical trial (NCT01737697) in patients with hyperkalemia (5 to 6.5 mEq/L, mean potassium 5.3 mEq/L), Study 1.

In the first phase of the trial (the acute phase), 753 patients were randomized to receive one of four doses of LOKELMA (1.25, 2.5, 5 or 10 g) or placebo, administered three times daily for the initial 48 hours with meals.

The mean age of patients was 66 years, 59% of patients were men, and 86% were Caucasian. Approximately 60% of patients had chronic kidney disease, 10% had heart failure, 62% had diabetes mellitus and 67% were on renin angiotensin aldosterone system (RAAS) inhibitor therapy at baseline.

The primary endpoint in the acute phase was the difference in the exponential rate of change in serum potassium levels during the initial 48 hours of study drug treatment, comparing placebo-treated patients and LOKELMA-treated patients. The study met its primary endpoint demonstrating a greater reduction in serum potassium levels for the 2.5, 5 and 10 g (three times a day) dose groups compared to the placebo group (p<0.001). As displayed in Table 1 for the secondary endpoint of potassium change from baseline, LOKELMA showed dose-dependent reductions in serum potassium at 2.5, 5 and 10 g. In patients administered 10 g TID, the mean serum potassium reduction was -0.7 mEq/L at 48 hours. Patients with higher starting potassium levels had a greater response to LOKELMA. LOKELMA was effective in lowering potassium levels in patients with chronic kidney disease, heart failure, diabetes mellitus and those taking RAAS inhibitor therapy.

Patients who achieved a potassium level between 3.5 and 5 mEq/L after receiving LOKELMA during the acute phase were re-randomized to receive once daily placebo or 1.25, 2.5, 5 or 10 g of once daily LOKELMA for 12 days together with breakfast.

The primary endpoint in the maintenance phase was the difference in the exponential rate of change in serum potassium levels over the 12-day treatment interval, comparing patients receiving LOKELMA and patients receiving placebo. The study met the primary efficacy endpoint at the 5 and 10 g doses when compared with their respective placebo groups (p<0.01 and p<0.001).
The standardised test meal was prepared in a single dose using Knorr low sodium chicken stock cubes (9g = 1 stock cube), 67.78g of plant protein and fibre variety 3 (3.09g leucine), 27.79g butter, 4.63g cornflour, and 300ml water. The test meal is consumed in a single sitting in the morning following an overnight fast. Blood samples are acquired at baseline and at set intervals over the subsequent 3-hours to examine the net peripheral amino acid appearance.
PURPOSE: Jujube extract-contained composites are provided to drop blood cholesterol by inhibiting the activity of cholesterol ester transfer protein(CETP) for the prevention and the treatment of various vascular diseases. CONSTITUTION: Jujubes are extracted by using acetone and filtered to get filtrate. The filtrate is compressed and concentrated. Hexane is added to the concentrate to separate into a water layer and a hexane layer. Ethyl acetate is added to the water layer containing active substances for separating into a water layer and an ethyl acetate layer. The collected ethyl acetate layer is concentrated and dried under a compressing condition. The concentrate is eluted with water, a water and methanol mixture, and acetonitrile to get active substances from acetonitrile fragmentation.